tbuckley/cabot-search huggingface dataset:
Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM).
Authors: Tanya Marya Wildes, Sascha Alexander Tuchman, Brittany Depp, Ling Chen, Keith Stockerl-Goldstein, Ravi Vij, Graham A. Colditz
Journal: Journal of Clinical Oncology (2015)

e20525 Background: MM is a disease of older adults, with two-thirds of cases diagnosed over age 65. In general oncology patients (pts), GA adds to information obtained in routine clinical practice and is predictive of chemotherapy toxicity and survival. The prevalence of geriatric syndromes detected by GA [comorbidities, functional dependence, depression, falls and cognitive & sensory impairment] and their relationship to ASCT eligibility in older adults with MM is unknown. Methods: In a two-institution pilot cohort study, patients aged ≥ 65 years with MM diagnosed within 3 months underwent GA, including assessment of physical performance (Timed Up and Go/TUG), Karnofsky Performance Status (KPS), Instrumental Activities of Daily Living (IADLs), Charlson Comorbidity Index (CCI), falls, cognition (Blessed OMC), depression, and quality of life. Based on clinical judgment, the treating physician categorized participants as eligible or ineligible for ASCT. Results: From 9/2012 – 12/2014, 39 pts enrolled; 61.5% were male, 79.5% white. ISS stage was I in 23%, II in 33%, III in 28%, unknown in 15%. Geriatric syndromes were common: 61.5% were dependent in ≥ 1 IADL, 28.9% fell in the prior 6-months, 56% involuntary weight loss, 28.9% depression, 10.3% cognitive impairment. Polypharmacy was rampant (median 9 meds, range 1-23). Sensory impairment was common: 27% and 29.7% reported their vision and hearing as fair or worse, respectively. ASCT-eligibility did not differ by gender, race/ethnicity, ISS stage, cytogenetics/FISH, or IADL dependence. ASCT-ineligible pts were older (median 73 vs 68, p = 0.047), had lower median KPS (70 vs 80, p = 0.04), slower time on the TUG (median 14.5 seconds vs 10.8, p = 0.048), more comorbidities (CCI ≥ 1 in 84.6% of ASCT-ineligible vs 30.8% of ASCT-eligible, p = 0.002) and reported poorer baseline quality of life on the FACT-GOG/NTX functional well-being scale (median 12 vs 18, p = 0.006). Conclusions: Geriatric syndromes are common in older adults with recently diagnosed MM. In addition to age and KPS, the TUG and CCI were associated with ASCT eligibility. Future studies will examine changes in functional status and quality of life over time.
SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study
Authors: Giulia Tosetti, Alessandro Loglio, Elisabetta Degasperi, Roberta D’Ambrosio, Mauro Viganò, Massimo Iavarone, Marta Borghi, Roberta Soffredini, Floriana Facchetti, Maria Grazia Rumi, Massimo Primignani, Pietro Lampertico
Journal: Journal of Hepatology (2019)
Erosive Pustular Dermatosis of the Scalp
Authors: Irina Elena Nasturica, Iuliana Busila, Aimilios Lallas
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Tau Positron-Emission Tomography in Former National Football League Players
Authors: Robert A. Stern, Charles H. Adler, Kewei Chen, Michael Navitsky, Ji Luo, David W. Dodick, Michael L. Alosco, Yorghos Tripodis, Dhruman D. Goradia, Brett Martin, Diego Mastroeni, Nathan G. Fritts, Johnny Jarnagin, Michael D. Devous, Mark A. Mintun, Michael J. Pontecorvo, Martha E. Shenton, Eric M. Reiman
Journal: New England Journal of Medicine (2019)

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been associated with a history of repetitive head impacts. The neuropathological diagnosis is based on a specific pattern of tau deposition with minimal amyloid-beta deposition that differs from other disorders, including Alzheimer's disease. The feasibility of detecting tau and amyloid deposition in the brains of living persons at risk for CTE has not been well studied.We used flortaucipir positron-emission tomography (PET) and florbetapir PET to measure deposition of tau and amyloid-beta, respectively, in the brains of former National Football League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with no history of traumatic brain injury. Automated image-analysis algorithms were used to compare the regional tau standardized uptake value ratio (SUVR, the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference) between the two groups and to explore the associations of SUVR with symptom severity and with years of football play in the former-player group.A total of 26 former players and 31 controls were included in the analysis. The mean flortaucipir SUVR was higher among former players than among controls in three regions of the brain: bilateral superior frontal (1.09 vs. 0.98; adjusted mean difference, 0.13; 95% confidence interval [CI], 0.06 to 0.20; P<0.001), bilateral medial temporal (1.23 vs. 1.12; adjusted mean difference, 0.13; 95% CI, 0.05 to 0.21; P<0.001), and left parietal (1.12 vs. 1.01; adjusted mean difference, 0.12; 95% CI, 0.05 to 0.20; P = 0.002). In exploratory analyses, the correlation coefficients in these three regions between the SUVRs and years of play were 0.58 (95% CI, 0.25 to 0.79), 0.45 (95% CI, 0.07 to 0.71), and 0.50 (95% CI, 0.14 to 0.74), respectively. There was no association between tau deposition and scores on cognitive and neuropsychiatric tests. Only one former player had levels of amyloid-beta deposition similar to those in persons with Alzheimer's disease.A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels. Further studies are needed to determine whether elevated CTE-associated tau can be detected in individual persons. (Funded by Avid Radiopharmaceuticals and others.).
SAT-458-Subtraction arterial images of hepatocyte-specific contrast-enhanced MRI: Added value for the diagnosis of hepatocellular carcinoma in the liver imaging reporting and data system v2018
Authors: Sang Hyun Choi, Dong Hwan Kim, Jae Ho Byun, So Jung Lee, So Yeon Kim, HyungJin Won, Yong Moon Shin, Pyo-Nyun Kim
Journal: Journal of Hepatology (2019)
Publisher Correction: A whole-brain atlas of monosynaptic input targeting four different cell types in the medial prefrontal cortex of the mouse
Authors: Sofie Ährlund-Richter, Yang Xuan, Josina Anna van Lunteren, Hoseok Kim, Cantin Ortiz, Iskra Pollak Dorocic, Konstantinos Meletis, Marie Carlén
Journal: Nature Neuroscience (2019)
Detection of colistin resistance mcr-1 gene in Salmonella enterica serovar Rissen isolated from mussels, Spain, 2012­ to 2016
Authors: Antonio Lozano-Leon, Carlos Garcia-Omil, Jacobo Dalama, Rafael Rodriguez-Souto, Jaime Martinez-Urtaza, Narjol Gonzalez-Escalona
Journal: Eurosurveillance (2019)

Nineteen Salmonella strains were isolated from 5,907 randomly selected mussel samples during a monitoring programme for the presence of Salmonella in shellfish in Galicia, north-west Spain (2012-16). Serovars, sequence type and antimicrobial resistance genes were determined through genome sequencing. Presence of the mcr-1 gene in one strain belonging to serovar Rissen and ST-469 was identified. The mcr-1 gene had not been isolated previously in environmental Salmonella isolated from mussels in Spain.
THU-098-Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?
Authors: Daniela van Santen, Jennifer Hoy, Paul Agius, David Iser, Mark O'reilly, Joe Sasadeusz, Mark Stoove, Janine Roney, Richard Moore, Tee Bk, Nick Medland, Christopher Fairley, Edward Gane, Gail Matthews, Maria Prins, Margaret Hellard, Joseph Doyle
Journal: Journal of Hepatology (2019)
Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma
Authors: Drew Spencer, Dou Yu, Ramin A. Morshed, Gina Li, Katarzyna C. Pituch, David X. Gao, Nicola Bertolino, Daniele Procissi, Maciej S. Lesniak, Irina V. Balyasnikova
Journal: Theranostics (2019)

Glioblastoma (GBM) remains the most lethal and untreatable central nervous system malignancy.The challenges to devise novel and effective anti-tumor therapies include difficulty in locating the precise tumor border for complete surgical resection, and rapid regrowth of residual tumor tissue after standard treatment.Repeatable and non-invasive intranasal application of neural stem cells (NSCs) was recently shown to enable clinically relevant delivery of therapy to tumors.Treatment with chemotactic NSCs demonstrated significant survival benefits when coupled with radiation and oncolytic virotherapy in preclinical models of GBM.In order to further augment the clinical applicability of this novel therapeutic platform, we postulate that the FDA-approved compound, methimazole (MT), can be safely utilized to delay the nasal clearance and improve the ability of NSCs to penetrate the olfactory epithelium for robust in vivo brain tumor targeting and therapeutic actions.METHODS: To examine the role of reversible reduction of the olfactory epithelial barrier in non-invasive intranasal delivery, we explored the unique pharmacologic effect of MT at a single dosage regimen.In our proof-of-concept studies, quantitative magnetic resonance imaging (MRI), immunocytochemistry, and survival analysis were performed on glioma-bearing mice treated with a single dose of MT prior to intranasal anti-GBM therapy using an oncolytic virus (OV)-loaded NSCs.RESULTS: Based on histology and in vivo imaging, we found that disrupting the olfactory epithelium with MT effectively delays clearance and allows NSCs to persist in the nasal cavity for at least 24 h.MT pretreatment amplified the migration of NSCs to the tumor.The therapeutic advantage of this enhancement was quantitatively validated by tissue analysis and MRI tracking of NSCs loaded with superparamagnetic iron oxide nanoparticles (SPIOs) in live animals.Moreover, we observed significant survival benefits in GBM-bearing mice treated with intranasal delivery of oncolytic virus-loaded NSCs following MT injection.Conclusion: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.
Serum galectin‐1, galectin‐3, and galectin‐9 are bystander molecules for chronic spontaneous urticaria
Authors: Lin Zheng, Zhen‐Rui Shi, Yan‐Fang Han, Yi‐Jin Luo, Zeng‐Qi Tang, Guo‐Zhen Tan, Liangchun Wang
Journal: Allergy (2019)
Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer
Authors: Hao Yu, Huanmei Wu, Weili Wang, Shruti Jolly, Jian-Yue Jin, Chen Hu, Feng-Ming (Spring) Kong
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Radiation pneumonitis is an important adverse event in patients with non–small cell lung cancer (NSCLC) receiving thoracic radiotherapy. However, the risk of radiation pneumonitis grade ≥ 2 (RP2) has not been well predicted. This study hypothesized that inflammatory cytokines or the dynamic changes during radiotherapy can improve predictive accuracy for RP2. Experimental Design: Levels of 30 inflammatory cytokines and clinical information in patients with stages I–III NSCLC treated with radiotherapy were from our prospective studies. Statistical analysis was used to select predictive cytokine candidates and clinical covariates for adjustment. Machine learning algorithm was used to develop the generalized linear model for predicting risk RP2. Results: A total of 131 patients were eligible and 17 (13.0%) developed RP2. IL8 and CCL2 had significantly (Bonferroni) lower expression levels in patients with RP2 than without RP2. But none of the changes in cytokine levels during radiotherapy was significantly associated with RP2. The final predictive GLM model for RP2 was established, including IL8 and CCL2 at baseline level and two clinical variables. Nomogram was constructed based on the GLM model. The model's predicting ability was validated in the completely independent test set (AUC = 0.863, accuracy = 80.0%, sensitivity = 100%, specificity = 76.5%). Conclusions: By machine learning, this study has developed and validated a comprehensive model integrating inflammatory cytokines with clinical variables to predict RP2 before radiotherapy that provides an opportunity to guide clinicians.
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in tongue cancer.
Authors: Kyoichi Kaira, Minoru Toyoda, Yasuhiro Ohshima, Noboru Oriuchi, Yoshikatsu Kanai, Tetsunari Oyama, Masanobu Yamada, Takayuki Asao, Kazuaki Chikamatsu
Journal: Journal of Clinical Oncology (2015)

e22204 Background: Amino acid transporters are necessary for the tumor cell growth and survival, and play a crucial role in the development and invasiveness of cancer cells. But, it remains unclear about the prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with tongue cancer. This study was conducted to determine biological significance of LAT1 expression and investigate whether LAT1 could be a prognostic biomarker for tongue cancer. Methods: Eighty-five patients with surgically resected tongue cancer were evaluated. Tumor sections were stained by immunohistochemistry for LAT1, ASCT2, xCT, CD98, CD147, Ki-67, microvessel density (MVD) determined by CD34, and p53. Biological significance of LAT1 expression was investigated by in vitro experiments with LAT inhibitor, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) using tongue cell line. Results: LAT1, ASCT2, xCT, CD98 and CD147 were highly expressed in 61% (52/85), 59% (50/85), 21% (18/85), 45% (38/85) and 33% (28/85), respectively. The expression of LAT1 was significantly associated with disease staging, lymph node metastasis, lymphatic permeation, cell proliferation (Ki-67), and the expression level of CD98, ASCT2 and CD147 as amino acid transporter complexes. Multivariate analysis confirmed that LAT1 was an independent prognostic factor for predicting poor prognosis. In vitro preliminary experiment indicated that BCH significantly suppressed growth of the tumor and yielded an additive therapeutic efficacy to cisplatin. Conclusions: LAT1 can serve as a promising pathological marker to predict the outcome in patients with tongue cancer. Inhibition of LAT1 may be an effective targeted therapy for this distressing disease.
Effect of circulating tumor cells (CTCs) on metastatic progression in colorectal cancer.
Authors: Yuri Gevorkyan, Oleg Ivanovich Kit, Inna Arnoldovna Novikova, Natalya Soldatkina, Andrey Vladimirovich Bakhtin, Pavel B. Shulikov, Anton G. Milakin, Vladimir Kolesnikov, Sergei A. Ilchenko
Journal: Journal of Clinical Oncology (2015)

e22026 Background: The purpose of the study was to analyze the content and to assess prognostic value of CTCs in peripheral blood of colorectal cancer patients with liver metastases. Methods: 75 colorectal cancer patients with resectable liver metastases Т2-4N0-1M1 (adenocarcinoma G2-G3), mean age 63.7±1.9 years, were recruited. Quantitative analysis of CTCs in peripheral blood was performed using CellSearch Veridex System (Janssen) 10 days after colon surgery and liver resection. CTCs were registered taking into account morphologic characteristics and expression of epithelial cell adhesion markers EpCAM, CD45 and cytokeratins 8, 18, 19. A blood sample containing ≥ 3 tumor cells was considered positive. Results: CTCs were found in 86.7% (65 patients of 75): 1-3 cells – 60% (39 patients), over 3 cells – 40% (26 patients). 25 (38.5%) of 65 patients with CTCs had G2 adenocarcinoma, 40 (61.5%) – G3 adenocarcinoma. 3-10 CTCs – 16 (61.5%) patients, over 10 CTCs – 10 (38.5%) patients; the maximum amount of CTCs was 402 cells. All patients received multi-course FOLFOX chemotherapy and underwent intensive follow-up with a thorough clinical examination, abdominal ultrasound and spiral computed tomography or magnetic resonance imaging of the abdomen every 3 months. During the 6 month observation period, patients with < 3 CTCs did not show progression of the liver metastasis, while it progressed in 100% of patients with > 3 CTCs. Conclusions: Surgery was considered as optimal cytoreductive one in < 3 CTCs level; in > 3 CTCs level, metastatic progression can be predicted and a more intensive therapy with a possible inclusion of targeted agents can be recommended.
THU-438-The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis
Authors: Zobair Younossi, Maria Stepanova, Manuel Romero Gomez, Takeshi Okanoue, Michael Trauner, Stephen Djedjos, Robert Myers, Issah Younossi, Andrei Racilla, Fatema Nader
Journal: Journal of Hepatology (2019)
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
Authors: Irene Cortese, Pawel Muranski, Yoshimi Enose-Akahata, Seung-Kwon Ha, Bryan Smith, MariaChiara Monaco, Caroline Ryschkewitsch, Eugene O. Major, Joan Ohayon, Matthew K. Schindler, Erin Beck, Lauren B. Reoma, Steve Jacobson, Daniel S. Reich, Avindra Nath
Journal: New England Journal of Medicine (2019)

Progressive multifocal leukoencephalopathy (PML) is an opportunistic brain infection that is caused by the JC virus and is typically fatal unless immune function can be restored. Programmed cell death protein 1 (PD-1) is a negative regulator of the immune response that may contribute to impaired viral clearance. Whether PD-1 blockade with pembrolizumab could reinvigorate anti-JC virus immune activity in patients with PML was unknown.We administered pembrolizumab at a dose of 2 mg per kilogram of body weight every 4 to 6 weeks to eight adults with PML, each with a different underlying predisposing condition. Each patient received at least one dose but no more than three doses.Pembrolizumab induced down-regulation of PD-1 expression on lymphocytes in peripheral blood and in cerebrospinal fluid (CSF) in all eight patients. Five patients had clinical improvement or stabilization of PML accompanied by a reduction in the JC viral load in the CSF and an increase in in vitro CD4+ and CD8+ anti-JC virus activity. In the other three patients, no meaningful change was observed in the viral load or in the magnitude of antiviral cellular immune response, and there was no clinical improvement.Our findings are consistent with the hypothesis that in some patients with PML, pembrolizumab reduces JC viral load and increases CD4+ and CD8+ activity against the JC virus; clinical improvement or stabilization occurred in five of the eight patients who received pembrolizumab. Further study of immune checkpoint inhibitors in the treatment of PML is warranted. (Funded by the National Institutes of Health.).
FRI-206-Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos (t)ide analogues
Authors: Milan Sonneveld, Gertine Oord, Margo J.H. van Campenhout, Robert De Man, Harry Janssen, Robert De Knegt, Annemiek Van Der Eijk, Andre Boonstra
Journal: Journal of Hepatology (2019)
Outcomes of inpatient palliative care consultations for advanced pancreatic and hepatobiliary cancer patients at an academic medical center.
Authors: Sandra Patricia Susanibar Adaniya, Joyce Johnsrud, Heather C Moore, Sarah Elizabeth Harrington
Journal: Journal of Clinical Oncology (2015)

e20547 Background: Use of hospice for end of life (EOL) care contributes to achieving good death in patients with cancer. The purpose of our study was to assess outcomes of inpatient palliative care consultation (PCC) on discharge disposition for patients with advanced pancreatic and hepatobiliary cancer who received treatment an academic medical center. Methods: Retrospective cohort study of adult patients with advanced pancreatic cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma who received their first PCC during an unscheduled hospitalization at the largest teaching hospital in Arkansas from 2011 to 2013. Data on patient demographics, clinical characteristics, discharge disposition, hospice use and place of death were collected. Results: Of 110 patients identified, 3 were excluded due to incomplete data. Median age was 77 years. Sixty-one percent were male; 70% Caucasian and 28% African-American; 49% had pancreatic cancer, 33% HCC and 19% cholangiocarcinoma. The median survival from diagnosis of advanced cancer to PCC and death were 82 (0-1228) and 138 (2-1331) days, respectively. The median survival from PCC to death was 15 (1-433) days. The most common reason for PCC (62%) was discussion of goals of care (GOC). At the time of discharge, 52% patients were enrolled to hospice. In 27% of these patients, the decision to enroll in hospice was made by the family. Overall, 78% were enrolled in hospice prior to death (46% inpatient hospice, 48% home hospice, 6% used both). The median hospice use was 8 (2-251) days. GOC discussion was associated with hospice enrollment at discharge (p = 0.036). Referral by oncology was associated to increased rates of hospice enrollment at discharge (p = 0.009) and use of home hospice for the end of life care (p = 0.03). Conclusions: Among patients with advanced pancreatic and hepatobiliary cancer, inpatient PCC occurs late and most commonly to discuss GOC. In 27% of the cases, the patients were not involved in the decision to enroll in hospice. A partnership between oncology and palliative care showed beneficial effects in achieving higher rates of hospice use near the end of life.